BridgeBio Showcase Long-Term ATTRibute-CM Data Highlighting Acoramidis’ Impact On Mortality, Biomarkers And Quality Of Life

BridgeBio Pharma, Inc. announced new long-term results from its ATTRibute-CM open-label extension study, highlighting the sustained efficacy and safety of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The findings, presented at the American College of Cardiology Annual Scientific Sessions & Expo, showcased data up to 54 months and were featured as a late-breaking oral presentation, underscoring their clinical significance.

The study demonstrated that continuous treatment with acoramidis significantly reduced the risk of all-cause mortality by 44.7% and cardiovascular mortality by 49.3% compared to patients who initially received placebo. Additionally, the therapy effectively controlled the rise of NT-proBNP levels, a key biomarker of heart failure, and maintained patient quality of life as measured by KCCQ-OS scores over the long term. These results suggest that early and consistent use of acoramidis can provide durable clinical benefits.

“Despite dramatic therapeutic advances in the field, many patients with ATTR-CM still continue to suffer progressive heart failure, high mortality risk, and many have limited long-term treatment options,” said Dr. Soman. “The ATTRibute-CM long-term data show that early and continuous treatment with acoramidis can meaningfully change the trajectory of this disease, with sustained reductions in all-cause and cardiovascular mortality, cardiovascular hospitalization, continued mitigation of NT-proBNP progression, and a favorable long-term safety profile. These findings reinforce the importance of early diagnosis followed by prompt, durable treatment to deliver sustained clinical benefit for patients.”

Further analyses presented at the conference reinforced these outcomes. Data showed that early treatment helped stabilize serum transthyretin (sTTR) levels and heart failure-related health status. Another study linked early increases in sTTR levels with slower disease progression, while real-world survey findings highlighted ongoing gaps in ATTR-CM treatment, including limited patient access and physician dissatisfaction with existing options.

Acoramidis also maintained a strong safety profile over the extended study period, with no new long-term concerns identified. The drug, approved under the brand names Attruby® in the U.S. and BEYONTTRA® in multiple global markets, continues to demonstrate its potential as a disease-modifying therapy for ATTR-CM, particularly when initiated early in the disease course.